The global proteomics market size was valued at USD 22.30 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 13.5% from 2022 to 2030. Key factors driving the industry growth include growing demand for personalized medicines & advanced diagnostics in targeted disease treatment and the high prevalence of target diseases. Furthermore, increasing focus on product usage in drug designing, biomarker discoveries, and clinical diagnostics for the diagnosis and treatment of diseases will support the industry growth. The market growth is also favored by the protein research being conducted to treat COVID-19 patients.
For instance, in June 2022, A novel class of synthetic peptides or mini-proteins has been developed by scientists at the Indian Institute of Science (IISc) Bangalore, and the researchers claim that it has the potential to neutralize viruses like SARS-CoV-2.Furthermore, a study published in the journal Nature Chemical Biology, claims that the mini-proteins can prevent virus entry into human cells as well as cluster virus particles together to lessen their infectious potential. Therefore, the industry is anticipated to benefit from the rising research on peptide therapies, and is projected to increase due to the COVID-19 pandemic.
In addition, the global industry is projected to expand rapidly over the next several years as a result of technical advancements, increased funding for research, rising healthcare costs, growing demand for tailored medication, and rising rates of genetic illnesses. For instance, in August 2020, the NCI’s Small Business Innovation Research (SBIR) Development Center announced funding that was inspired by the Clinical Proteomic Tumor Analysis Consortium (CPTAC). The announcement urges the creation of single-cell, high-throughput proteome discovery tools. This opportunity aims to increase the understanding of how cancer develops and progresses while also enabling robust cancer biomarker discovery and clinical use on a micro-scale.
The rising prevalence of chronic diseases like cancer, Cardiovascular Diseases (CVDs), respiratory diseases, CKD, and others is another factor anticipated to propel the market growth. For instance, according to Globocan, in December 2020, there were 19.3 million new cases of cancer across the world and 10 million cancer-related deaths were reported. Similarly, CVDs are one of the major causes of death worldwide. For instance, as per the WHO (2021), target diseases kill 41 million patients per year. Thus, owing to the increasing prevalence of life-threatening diseases, the demand for personalized therapies is also increasing resulting in a positive impact on the industry.
Increased investments by major players in the production of advanced & effective drugs and diagnostic tools are likely to support market growth throughout the projected timeframe. For instance, in June 2021, Bruker Corp. launched the two new timsTOF instruments. It enables new methods & applications, such as epiproteomics/PTM characterization, and unbiased, and, deep multi-omic biomarker discovery. Also, in cancer liquid biopsy research, they further enhance and facilitate these novel applications and techniques. Such initiatives by companies are likely to supplement the industry growth in the coming years.
The reagents & consumables segment accounted for the highest share of more than 70.30% of the global revenue in 2021. The segment is anticipated to exhibit the fastest growth rate during the projected period. This is attributed to the extensive use of reagents & consumables, kits, chemicals, and strips for the examination of various biological samples in academic institutions, research labs, and others, which will increase the demand for reagents & consumables fueling the segment growth. In addition, technological developments of advanced instruments, such as 2-D electrophoresis protein analyzers, which improve the speed, efficiency, and throughput of biological research, would also support the market growth.
Electrophoresis equipment and biochip analyzers are the commonly used instruments for protein analysis. Furthermore, the increasing demand for automation in diagnostic techniques and the need for a cost-effective platform for sample analysishave increased interest among manufacturers to focus on innovations and product development. Moreover, technological breakthroughs (the growing downsizing and integration of biochips as well as advancements in the instruments and workflows for mass spectrometry) in proteomics instruments are expected to drive market trends over the years to come.
The clinical diagnostics segment dominated the industry with a share of more than 51.65% in 2021. This is attributed to the high adoption of protein analysis among clinical researchers to identify disease biomarkers for the early detection of the disease, and identifying individual risk factors. This is expected to create new opportunities for prevention and early intervention of the disease. With the help of proteomics-based diagnosis, it is possible to uncover potential biomarkers and protein expression patterns that can be used to classify and predict tumors, and determine their prognosis, which further contributes to the segment’s growth.
On the other hand, the drug discovery segment is estimated to register the fastest growth rate during the projected period. The development of structure-based drug design, a greater emphasis on creating personalized drugs, and more investments in these areas can all be credited for the segment growth. In addition, proteomics technologies also offer a way to show early on in a drug discovery program, saving pharmaceutical corporations a significant amount of capital and eventually benefiting patients as well as the healthcare systems, which contributes to the segmentgrowth.
On the basis of technologies, the industry has been further divided into microarray instruments, x-ray crystallography, spectroscopy, chromatography, protein fractionation systems, electrophoresis, and Surface Plasma Resonance (SPR) systems. The spectroscopy segment captured the highest revenue share of more than 47.00% in 2021.It is projectedto expand further at the fastest growth rate during the forecast period. Key factors driving the segment growth include the vast usage of spectroscopy-based technologies employed in many analytical applications, including drug development processes, proteomics, metabolomics, forensic analysis, and pharmaceutical analysis.
In recent years, this method has become more widely used at various stages of the drug development process. For instance, in May 2020, researchers from the University of Surrey used the MS method to expedite and aid in the development of the COVID-19 vaccine. An increase in the use of microarrays in various applications is anticipated to supplement the industry growth. For instance, the use of microarray analysis in antibiotic therapy has shown to be successful since, in most cases, bacterial genomic DNA outlives the survival of bacteria. The preferred technique for determining gene expression has recently been the use of DNA-based microarrays. This is primarily attributable to elements like complexity and cost reduction that make the technology more widely available and uniform.
North America dominated the industry with the largest revenue share of 45.90% in 2021. This is attributed to the increased investments in the development of structure-based drug design, growth in omics research, demand for high-quality research tools for data reproducibility, and attention to the development of tailored treatments. The expansion of this market is also being aided by the partnerships and collaborations amongmajor companies in this region. For instance, Thermo Fisher Scientific Inc. and Symphogen collaborated to develop verified platform processes for the streamlined characterization and quality monitoring of complex therapeutic proteins.
This continued agreement was announced in March 2022.The Asia Pacific region is estimated to grow at the fastest CAGR from 2022 to 2030 due to an increase in outsourcing of proteomics-based projects, public and private funding for research and development for proteomics studies, favorable government regulations, rising prevalence of target diseases with an aging population, and rising proteomics adoption. For instance, the University of Hyderabad received 60 million in funding from the Department of Biotechnology of the Indian government in November 2021 to study the proteome of tomatoes. The market in Asia Pacific is being driven by such government measures to support the proteomics study.
Key players are implementing various strategies including partnerships through mergers & acquisitions, geographical expansion, and strategic collaborations to enhance their industry presence. For instance, in January 2022, The Proteograph Product Suite’s Broad Commercial Release and the Centers of Excellence program’s debut were both announced by Seer, Inc. The Proteograph Product Suite offers impartial, unmatched access to the proteome. The approach uses unique designed nanoparticles to produce a ground-breaking product that enables quick, thorough, and unbiased proteomics at scale.Some of the key players in the global proteomics market include:
Agilent Technologies, Inc.
Bio - Rad Laboratories, Inc.
Thermo Fisher Scientific, Inc.
F. Hoffmann-La Roche Ltd.
Market size value in 2022
USD 25.67 billion
Revenue forecast in 2030
USD 70.56 billion
CAGR of 13.5% from 2022 to 2030
Base year for estimation
2018 - 2020
2022 - 2030
Revenue in USD million/billion and CAGR from 2022 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Product, application, technology, region
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; Germany; U.K.; China; Japan; Brazil; South Africa
Key companies profiled
Illumina, Inc.; Agilent Technologies, Inc.; Bio-Rad Laboratories, Inc.; GE Healthcare; Thermo Fisher Scientific, Inc.; F. Hoffmann-La Roche Ltd.; Promega Corp.; Merck KGaA; Danaher
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2020 to 2030. For the purpose of this study, Grand View Research has segmented the global proteomics market report on the basis of product, application, technology, and region:
Product Scope Outlook (Revenue, USD Million, 2018 - 2030)
Reagents & Consumables
Application Scope Outlook (Revenue, USD Million, 2018 - 2030)
Technology Scope Outlook (Revenue, USD Million, 2018 - 2030)
Protein Fractionation Systems
Surface Plasma Resonance (SPR) Systems
Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East & Africa
b. The global proteomics market size was estimated at USD 22.30 billion in 2021 and is expected to reach USD 25.67 billion in 2022.
b. The global proteomics market is expected to grow at a compound annual growth rate of 13.5% from 2022 to 2030 to reach USD 70.56 billion by 2030.
b. The reagents and consumables segment dominated the proteomics market with a share of 70.33% in 2021. This is attributed to the factors such as widespread research in academic institutes coupled with high frequency of usage of reagents, kits, chemicals, and strips for the analysis of various biological samples.
b. Some key players operating in the proteomics market include Illumina, Inc., Agilent Technologies, Inc., Bio - Rad Laboratories, Inc., GE Healthcare, Thermo Fisher Scientific, Inc., Bruker Corporation, F. Hoffmann-La Roche Ltd., Promega Corporation, Merck KGaA, and Danaher.
b. Key factors that are driving the proteomics market growth include the rise in the geriatric population demanding personalized medicines, growing demand for advanced diagnostics in targeted disease treatment, growing prevalence of target diseases, growing demand for therapeutic medicines, and outbreak of COVID-19.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."